Silica Corpora

What's next for AI in 2025? ✨ There's huge potential for AI to transform the pharmaceutical industry by driving efficiency, reducing costs, and improving patient outcomes. Let’s check out some exciting predictions on how AI will shape pharma in 2025: 1️⃣ Drug Discovery & Development 💊 AI will speed up drug discoveries and help biotech companies manage larger drug pipelines, uncovering innovative targets 2️⃣ AI in Clinical Trials 📊 AI will streamline clinical trials, cutting costs by 70% and timelines by 80% 3️⃣ Precision Medicine 🧬 AI will advance personalized treatments, especially in oncology, by analyzing patient data to recommend the best therapies based on genetics 4️⃣ Regulatory Support & Market Value 📈 AI could generate $410 billion annually by 2025, boosting pharma innovation and improving patient care The future of pharma is AI-powered, and 2025 is just the beginning. 🌟 #AI #DrugDiscovery #SilicaCorpora

The Intersection of AI and Drug Development ⚙️ Check out this research paper on AI in Drug Development that was generated with the assistance of AI. https://lnkd.in/eDnRf2Mw It covers not only the benefits of AI but also the challenges that must be addressed, which includes data quality and ethical implications and limitations. What do you think about AI in drug discovery? Let's discuss comments. #DrugDevelopment #SilicaCorpora #Biotech

Merry Christmas from Silica Corpora! 🎄 As we approach the end of the year, we would like to thank everyone who has supported us through our journey. May this Christmas bring you joy, laughter, and cherished memories with loved ones ✨ #MerryChristmas #SilicaCorpora #TogetherForBetter

Did you know it took 11 years for the first monoclonal antibody created in mice to receive approval? Today, antibodies have transformed from experimental technology into a keystone of the biopharma industry and are widely used across immunology, including infectious disease, cancer, immuno-oncology, neuroscience, Alzheimer’s Disease and more. Yet scientists continue to face some key challenges: 🦠 Modality selection - The proliferation of new types of antibody-based therapies has seen the rise of novel modalities being adopted alongside established formats. Adopting promising new modalities can be challenging for drug developers working in an industry slow to change. 🦠Drug delivery - Finding ways to get antibody-based therapies across the blood-brain barrier will be vital to the success of drugs against neurological diseases and some cancers. 🦠Improving R&D efficiency - how to make better, earlier decisions and quickly deliver therapeutically-relevant candidates. As we look to the future, new AI-based modalities such as De Novo drug design promise to redefine how we develop therapies to treat diseases. Join us as we advance and shape the future of antibody therapies and accelerate innovation in healthcare 🌟 #SilicaCorpora #Biotech #antibodydevelopment

Let’s End the Year with Some Engagement 🌟 We want to hear your thoughts, what do you think is the biggest ethical concern regarding AI applications in biotech? Share your thoughts in the poll 🔬💬 #SilicaCorpora #Biotech #ethicalconsiderations

Silica Corpora at the ISPE SC Berlin Event! 🌟 Last Friday, our CTO, Tim Ermak, presented at HTW Berlin, sharing the vision of Silica Corpora and key insights with students and future leaders in the life sciences industry including: 🔑 A Turning Point: When Tim realized that a career in this field would suit him and what inspired that choice. 💬 Career Reflections: Valuable advice he would give to his younger self regarding his career and professional choices. Follow us for more insights and future presentations where you can engage directly with our Team. Check out some great moments from the event. #ISPE #SilicaCorpora #Biotech

2024 is almost over 🗓️ As we look back, we can clearly see a year filled with achievements and progress. 🏆 We look forward to 2025 and beyond as we continue to evolve our AI-powered antibody design platform and innovate alongside our partners. ”Success doesn't come from what you do occasionally, but what you do consistently.” — Marie Forleo We would like to thank everyone who is with us on this journey. Here’s to a great 2025! 🚀 #SilicaCorpora #journey #Biotech

Did you know that the same diseases can manifest differently from one population to another ❓ So why are we using the same medication for everyone ❓ At Silica Corpora we use AI-based De Novo technologies to design the right antibodies that people need, because one-size does not always fit all. 🚀 Check out the video below which shows how we are transforming healthcare by creating personalised treatments and a future where healthcare is truly one-to-one, for everyone. 💫 Join us and lets go #denovo #SilicaCorpora #Biotech #AntibodyEngineering

Mare than 1000-fold affinity improvement? Let’s Explore more! 👇 Our Optimizer module creates mutants of antibody candidates, significantly enhancing their binding properties and affinity. 🔍 Latest Achievements in Affinity Optimization: Our optimization process has demonstrated the potential to achieve more than 1000-fold improvement in binding affinity for single mutations in our candidates. Want to learn more about those achievements? Request our white paper today and discover how the Optimizer can transform your approach to therapeutic development! #SilicaCorpora #Biotech #drugdesign #whitepaper

Why fish for the right Antibody when you can design it? 🎣 With Silica Corpora’s AI-driven de novo drug design, we’re moving from uncertain, time-consuming processes to precision and speed. create your ideal catch, don’t just fish for it! #DrugDiscovery #BioTech #SilicaCorpora #denovo